New cancer drugs help Johnson & Johnson top profit estimates

October 17, 2017 by  
Filed under News

(Reuters) – Johnson & Johnson posted better-than-expected third-quarter earnings, raising its full-year forecast due to growth from new cancer drugs and high-margin treatments picked up in its $30 billion acquisition of Actelion earlier this year.

Source: Reuters Business News

Comments are closed.